Therapeutic Landscape for Patients With MF and JAK Inhibitor Failure
Download this slideset from a live symposium at ASCO 2023 to review expert perspectives on approved and investigational approaches to the treatment of patients with myelofibrosis and prior JAK inhibitor therapy.
Director, Adult Leukemia Program Leader, Myeloproliferative Disorders Clinical Research Program Division of Hematology/Oncology Tisch Cancer Institute Professor of Medicine Icahn School of Medicine at Mount Sinai New York, New York
Provided by Clinical Care Options, LLC
Supported by educational grants from AbbVie, Inc., CTI BioPharma, GSK, and Incyte Corporation.
Select date of attendance
Welcome to the CCO site
Thank you for your interest in CCO content. As a guest, please complete the following information. This data helps ensure our continued delivery of impactful medical education.
You will be sent to the previous page if you close this window.